Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on TQ05105 PK in Healthy Adults
NCT05982106Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rovadicitinib in myelofibrosis (MF) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Area under the drug-time curve at 24 hours and Maximum Concentration at 24 hours. Started Jul 2021; status: completed.
02
Drugs
rovadicitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05982106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05982106.